Supernus Pharmaceuticals Q3 Swings to Profit, Revenue Increases; 2024 Revenue Outlook Lifted

MT Newswires Live11-05

Supernus Pharmaceuticals (SUPN) reported Q3 earnings late Monday of $0.69 per diluted share, swinging from a loss of $0.29 a year earlier.

A single analyst polled by Capital IQ expected $0.02.

Revenue for the quarter ended Sept. 30 was $175.7 million, up from $153.9 million a year earlier.

Four analysts surveyed by Capital IQ expected $157.3 million.

For 2024, the life sciences company raised its revenue guidance to between $630 million to $650 million, from the previous range of $600 million to $625 million. Four analysts polled by Capital IQ expect $642.2 million.

Shares of the company were up more than 6% in recent Tuesday premarket activity.

Price: 37.00, Change: +2.30, Percent Change: +6.63

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481452578?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-05 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481452578","market":"sg","top_or_hot":-1,"title":"Supernus Pharmaceuticals Q3 Swings to Profit, Revenue Increases; 2024 Revenue Outlook Lifted","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a> (SUPN) reported Q3 earnings late Monday of $0.69 per diluted share, swinging from a loss of $0.29 a year earlier.</p><p>A single analyst polled by Capital IQ expected $0.02.</p><p>Revenue for the quarter ended Sept. 30 was $175.7 million, up from $153.9 million a year earlier.</p><p>Four analysts surveyed by Capital IQ expected $157.3 million.</p><p>For 2024, the life sciences company raised its revenue guidance to between $630 million to $650 million, from the previous range of $600 million to $625 million. Four analysts polled by Capital IQ expect $642.2 million.</p><p>Shares of the company were up more than 6% in recent Tuesday premarket activity.</p><p>Price: 37.00, Change: +2.30, Percent Change: +6.63</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supernus Pharmaceuticals Q3 Swings to Profit, Revenue Increases; 2024 Revenue Outlook Lifted</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupernus Pharmaceuticals Q3 Swings to Profit, Revenue Increases; 2024 Revenue Outlook Lifted\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-05 18:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Supernus Pharmaceuticals (SUPN) reported Q3 earnings late Monday of $0.69 per diluted share, swinging from a loss of $0.29 a year earlier.A single analyst polled by Capital IQ expected $0.02.Revenue ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SUPN","symbol_name":"Supernus Pharmaceuticals","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481452578","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481452578","pubTimestamp":1730802012,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Supernus Pharmaceuticals  reported Q3 earnings late Monday of $0.69 per diluted share, swinging from a loss of $0.29 a year earlier.A single analyst polled by Capital IQ expected $0.02.Revenue for the quarter ended Sept. 30 was $175.7 million, up from $153.9 million a year earlier.Four analysts surveyed by Capital IQ expected $157.3 million.For 2024, the life sciences company raised its revenue guidance to between $630 million to $650 million, from the previous range of $600 million to $625 million. Four analysts polled by Capital IQ expect $642.2 million.Shares of the company were up more than 6% in recent Tuesday premarket activity.Price: 37.00, Change: +2.30, Percent Change: +6.63","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"SUPN":"Supernus Pharmaceuticals"},"translate_title":"Supernus Pharmaceuticals第三季度扭亏为盈，收入增加；2024年收入前景上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":1},"content_text":"Supernus Pharmaceuticals (SUPN) reported Q3 earnings late Monday of $0.69 per diluted share, swinging from a loss of $0.29 a year earlier.A single analyst polled by Capital IQ expected $0.02.Revenue for the quarter ended Sept. 30 was $175.7 million, up from $153.9 million a year earlier.Four analysts surveyed by Capital IQ expected $157.3 million.For 2024, the life sciences company raised its revenue guidance to between $630 million to $650 million, from the previous range of $600 million to $625 million. Four analysts polled by Capital IQ expect $642.2 million.Shares of the company were up more than 6% in recent Tuesday premarket activity.Price: 37.00, Change: +2.30, Percent Change: +6.63","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481452578"}